<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068416</url>
  </required_header>
  <id_info>
    <org_study_id>004:TCELL</org_study_id>
    <secondary_id>2016-004043-36</secondary_id>
    <nct_id>NCT03068416</nct_id>
  </id_info>
  <brief_title>CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy</brief_title>
  <official_title>CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AFA Insurance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting&#xD;
      chimeric antigen receptor (CAR) T cells to evaluate for safety and efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting&#xD;
      chimeric antigen receptor (CAR) T cells to evaluate for safety and efficacy. The CAR consists&#xD;
      of a CD19 targeting antibody scFv with three intracellular signaling domains derived from CD3&#xD;
      zeta, CD28 and 4-1BB. Autologous T cells will be gene engineered with the CAR gene using a&#xD;
      retrovirus vector. Prior to T cell infusion, the patients will be subjected to&#xD;
      preconditioning treatment. After the second infusion patients will be subjected to&#xD;
      immunomodulatory treatment. After T cell infusion, the patients will be evaluated for 24&#xD;
      months for adverse reactions, persistence of CAR T cells and efficacy.&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      - Registration of the safety profile such as inflammation, fever, pain, changes in blood&#xD;
      pressure, pulse and other adverse events.&#xD;
&#xD;
      Weekly for the first 6 weeks, then at 3, 6, 9, 12, 15, 18, 21 and 24 months.&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      Tumor response, CAR T cell persistence and immunological profile&#xD;
&#xD;
        -  Determination of tumor size and the tumor marker CD19.&#xD;
&#xD;
        -  Determination of the levels of circulating B cells.&#xD;
&#xD;
        -  Determination of the level of CAR T cells (mRNA and cells) in blood and biopsies.&#xD;
&#xD;
        -  Determination of activation markers on CAR T cells such as CD107a.&#xD;
&#xD;
        -  Determination of the presence of immunological markers in blood and biopsies.&#xD;
&#xD;
      At 1 and 3 weeks then at 3, 6, 9, 12, 15, 18, 21 and 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2017</start_date>
  <completion_date type="Actual">August 19, 2021</completion_date>
  <primary_completion_date type="Actual">August 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>24 months.</time_frame>
    <description>Determination of tumor size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B cell levels</measure>
    <time_frame>24 months</time_frame>
    <description>Determination of circulating CD19+ B cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAR T cell persistence</measure>
    <time_frame>24 months</time_frame>
    <description>Determination of the level of CAR T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological profile</measure>
    <time_frame>24 months</time_frame>
    <description>Determination of frequencies of immune cells in patient blood and tissues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine profile</measure>
    <time_frame>24 months</time_frame>
    <description>Determination of cytokine profile in patient blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>B-cell Leukemia</condition>
  <condition>B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CAR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous 3rd generation CD19-targeting CAR T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR T cells</intervention_name>
    <description>Autologous CD19-targeting, 3rd generation CAR T cells</description>
    <arm_group_label>CAR T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed or refractory CD19+ B-cell lymphoma or leukemia with no other curative&#xD;
             treatment option available.&#xD;
&#xD;
          2. Measurable disease.&#xD;
&#xD;
          3. All ages&#xD;
&#xD;
          4. Performance status ECOG 0-2.&#xD;
&#xD;
          5. Fertile females/males must consent to use contraceptives during participation of the&#xD;
             trial.&#xD;
&#xD;
          6. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any significant medical or psychiatric illness that would prevent the patient from&#xD;
             giving informed consent or from following the study procedures.&#xD;
&#xD;
          2. Patients with primary CNS lymphoma.&#xD;
&#xD;
          3. Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          4. Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic&#xD;
             infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV)&#xD;
             infection.&#xD;
&#xD;
          5. Other serious underlying medical conditions, which, in the Investigator's judgment,&#xD;
             could impair the ability of the patient to perform the treatment.&#xD;
&#xD;
          6. Treatment with an investigational product within 30 days prior to enrollment, or at&#xD;
             least 5 half-lives of that drug, which is longest.&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Patients that do not consent to that tissue and blood samples are stored in a biobank&#xD;
&#xD;
          9. Patients whose cells cannot be manufactured.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunilla Enblad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital, Dept of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uppsala University Hospital, Dept of Oncology</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

